DSTN抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01288(DSTN Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P01288(DSTN Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

DSTN (destrin), also known as actin-depolymerizing factor (ADF), is a conserved cytoskeletal protein that regulates actin filament dynamics by severing and disassembling aged or damaged filaments. It plays a critical role in cell motility, cytokinesis, and tissue remodeling by promoting rapid actin turnover. Antibodies targeting DSTN are essential tools for studying its expression, localization, and function in physiological and pathological contexts.

DSTN antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate its role in diseases such as cancer metastasis, neurodegenerative disorders, and immune dysregulation. For instance, elevated DSTN levels are linked to enhanced cancer cell invasion, while its dysregulation is implicated in Alzheimer’s disease due to disrupted synaptic actin dynamics. These antibodies help identify post-translational modifications (e.g., phosphorylation) that modulate DSTN’s activity, offering insights into regulatory mechanisms.

Research utilizing DSTN antibodies has expanded understanding of cytoskeletal plasticity in development, wound healing, and immune cell migration. Commercial DSTN antibodies are typically validated for specificity across human, mouse, and rat models, ensuring broad applicability. Ongoing studies aim to explore DSTN as a therapeutic target or biomarker, emphasizing its translational potential in precision medicine.